(Q38166017)

30 August 2017

Emerging topical treatments for psoriasis (English)

1 reference

30 August 2017

Dario N Kivelevitch

1

1 reference

30 August 2017

Katherine R Hebeler

series ordinal

2

1 reference

30 August 2017

Mahir Patel

series ordinal

3

1 reference

30 August 2017

Alan Menter

series ordinal

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 December 2013

1 reference

Expert Opinion on Emerging Drugs

30 August 2017

1 reference

30 August 2017

18

1 reference

30 August 2017

4

1 reference

30 August 2017

523-532

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

30 August 2017

1 reference

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Topical treatments for chronic plaque psoriasis of the scalp: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Adverse effects of topical glucocorticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

New insights in the immunologic basis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

The JAK-STAT signaling pathway: input and output integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Emerging therapies for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (M

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Pan-selectin antagonism improves psoriasis manifestation in mice and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Vitamin D analogues and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Mechanisms of action of topical therapies and the rationale for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Adherence to topical treatment in psoriasis: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Adherence to medication in patients with psoriasis: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

Patients' educational needs about topical treatments for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.861418

10.1517/14728214.2013.861418

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference